StockData
NeoGenomics Inc logo

NeoGenomics Inc (NEO) stock

NEONasdaqServices-Testing LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 11/3023% below fair value
$15.25−0.16 (-1.04%)

Close on Nov 17, 2026Market cap $1.97BP/E –Yield –

Earnings

NeoGenomics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 16, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$209.00M
+11.2% on a year earlier
Adjusted diluted EPS (non-GAAP), Q3 FY2026
$0.07
$0.03 a year earlier
Latest guidance
Raised
Oct 28, 2026 · 6 items

Quarterly results

Revenue and earnings per share from each of NeoGenomics's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 16, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Oct 28, 2026after the close$209.00M+11.2%-$0.06$0.07Release
Q2 FY2026ended Jun 30, 2026Jul 28, 2026after the close$202.00M+11.6%$0.02$0.05Release
Q1 FY2026ended Mar 31, 2026Apr 28, 2026after the close$187.00M+11.3%-$0.13$0.01Release
Q4 FY2025ended Dec 31, 2025Feb 17, 2026before the open$190.00M+10.5%-$0.08$0.06Release
Q3 FY2025ended Sep 30, 2025Oct 28, 2025before the open$188.00M+11.9%-$0.21$0.03Release
Q2 FY2025ended Jun 30, 2025Jul 29, 2025before the open$181.00M+9.7%––Release
Q1 FY2025ended Mar 31, 2025Apr 29, 2025before the open$168.00M+7.7%-$0.20$0.00Release
Q4 FY2024ended Dec 31, 2024Feb 18, 2025before the open$172.00M+10.3%-$0.12$0.04Release
Q3 FY2024ended Sep 30, 2024Nov 5, 2024before the open$168.00M+10.5%-$0.14$0.05Release
Q2 FY2024ended Jun 30, 2024Jul 29, 2024after the close$165.00M+12.2%-$0.15$0.03Release
Q1 FY2024ended Mar 31, 2024Apr 30, 2024before the open$156.00M+13.9%-$0.21-$0.02Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

NeoGenomics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Consolidated revenueGAAPFY2026$807.00M – $809.00M–NewOct 28, 2026
Consolidated revenueFY2026$802.00M – $806.00M$797.00M – $803.00MRaisedJul 28, 2026
Consolidated revenueFY2026$793.00M – $801.00M–NewFeb 17, 2026
Adjusted EBITDAnon-GAAPFY2026$60.00M$55.00M – $57.00MRaisedOct 28, 2026
Adjusted EBITDAnon-GAAPFY2026$56.00M – $58.00M$55.00M – $57.00MRaisedJul 28, 2026
Net loss per diluted share (GAAP)GAAPFY2026-$0.25 – -$0.23-$0.48 – -$0.38RaisedOct 28, 2026
Net loss per diluted share (GAAP)GAAPFY2026-$0.32 – -$0.26-$0.48 – -$0.38RaisedJul 28, 2026
Adjusted diluted EPS (non-GAAP)non-GAAPFY2026$0.21 – $0.22$0.16 – $0.21RaisedOct 28, 2026
Adjusted diluted EPS (non-GAAP)non-GAAPFY2026$0.17 – $0.20$0.16 – $0.21NarrowedJul 28, 2026
Adjusted net income (non-GAAP)non-GAAPFY2026$27.00M – $28.00M–NewOct 28, 2026
Net lossGAAPFY2026-$32.00M – -$30.00M–NewOct 28, 2026
Net lossGAAPFY2026-$42.00M – -$34.00M-$63.00M – -$50.00MRaisedJul 28, 2026
Net lossFY2026-$63.00M – -$50.00M–NewFeb 17, 2026

Guidance vs results

The last range NeoGenomics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$720.00M – $726.00M$727.00MΣ4QAbove range

Guidance history

Every forecast NeoGenomics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 28, 2026Adjusted EBITDAFY2026$60.00MRaised
Oct 28, 2026Adjusted diluted EPS (non-GAAP)FY2026$0.21 – $0.22Raised
Oct 28, 2026Net loss per diluted share (GAAP)FY2026-$0.25 – -$0.23Raised
Oct 28, 2026Net lossFY2026-$32.00M – -$30.00MNew
Oct 28, 2026Adjusted net income (non-GAAP)FY2026$27.00M – $28.00MNew
Oct 28, 2026Consolidated revenueFY2026$807.00M – $809.00MNew
Jul 28, 2026Adjusted EBITDAFY2026$56.00M – $58.00MRaised
Jul 28, 2026Adjusted diluted EPS (non-GAAP)FY2026$0.17 – $0.20Narrowed
Jul 28, 2026Net loss per diluted share (GAAP)FY2026-$0.32 – -$0.26Raised
Jul 28, 2026Net lossFY2026-$42.00M – -$34.00MRaised
Jul 28, 2026Consolidated revenueFY2026$802.00M – $806.00MRaised
Apr 28, 2026Adjusted EBITDAFY2026$55.00M – $57.00MNew
Apr 28, 2026Adjusted diluted EPS (1) (non-GAAP)FY2026$0.16 – $0.21New
Apr 28, 2026Net loss per diluted share (GAAP)FY2026-$0.48 – -$0.38New
Apr 28, 2026Net lossFY2026-$63.00M – -$50.00MNew
Apr 28, 2026Consolidated revenueFY2026$797.00M – $803.00MNew
Feb 17, 2026Adjusted EBITDAFY2026$55.00M – $57.00MNew
Feb 17, 2026Adjusted diluted EPS (2) (non-GAAP)FY2026$0.16 – $0.21New
Feb 17, 2026Net loss per diluted share (GAAP)FY2026-$0.48 – -$0.38New
Feb 17, 2026Net lossFY2026-$63.00M – -$50.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases NeoGenomics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Update
  5. Update
  6. News
  7. News
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Update
  14. Results
  15. Results

See a number that looks wrong?